Current early diagnostic biomarkers of prostate cancer  

作　　者：Min Qu Shan-Cheng Ren Yinghao Sun 

机构地区：[1]Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.

出　　处：《Asian Journal of Andrology》2014年第4期549-554,共6页亚洲男性学杂志（英文版）

基　　金：This study was supported by the National Basic Research Program of China （No. 2012CB518306）, the National Natural Science Foundation of China （No. 81101946）, the Prostate Cancer Foundation Young Investigator Award, and the Shanghai Pujiang Program （No. 12PJD008）.

摘　　要：Prostate cancer （PCa） has become to have the highest incidence and the second mortality rate in western countries, affecting men＇s health to a large extent. Although prostate-specific antigen （PSA） was discovered to help diagnose the cancer in an early stage for decades, its specificity is relative low, resulting in unnecessary biopsy for healthy people and over-treatment for patients. Thus, it is imperative to identify more and more effective biomarkers for early diagnosis of PCa in order to distinguish patients from healthy populations, which helps guide an early treatment to lower disease-related mortality by noninvasive or minimal invasive approaches. This review generally describes the current early diagnostic biomarkers of PCa in addition to PSA and summarizes the advantages and disadvantages of these biomarkers.Prostate cancer （PCa） has become to have the highest incidence and the second mortality rate in western countries, affecting men＇s health to a large extent. Although prostate-specific antigen （PSA） was discovered to help diagnose the cancer in an early stage for decades, its specificity is relative low, resulting in unnecessary biopsy for healthy people and over-treatment for patients. Thus, it is imperative to identify more and more effective biomarkers for early diagnosis of PCa in order to distinguish patients from healthy populations, which helps guide an early treatment to lower disease-related mortality by noninvasive or minimal invasive approaches. This review generally describes the current early diagnostic biomarkers of PCa in addition to PSA and summarizes the advantages and disadvantages of these biomarkers.

关 键 词：early diagnostic biomarkers MALATl-derived miniRNA PCA3 prostate cancer PSA 

分 类 号：S858.23[农业科学—临床兽医学] Q78[农业科学—兽医学]